Sovargen
- Biotech or pharma, therapeutic R&D
Sovargen is a biotech company that develops first and best-in-class etiology-based precision medicines to suppress the refractory seizures associated with Focal Malformations of Cortical Development (FMCD).
Its lead compound SVG103 is the dual PI3K and mTOR inhibitor with remarkable BBB penetration and safety profile and is preparing for a Ph 1/2 trial in patients diagnosed with FCD-II, TSC, or HME.
We are seeking a global partner who can in-license or co-develop our asset.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}